logo

For the Inventor, By the Inventor

Tokyo, Japan

Nobufusa Serizawa

This inventor holds 11 USPTO granted patents. Top assignee: Sankyo Company, Limited. Active years: 1994-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nobufusa Serizawa. Retrieved from https://idiyas.com/inventor/nobufusa-serizawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 81.8

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 38(Granted Patents)


Location History:

  • Tokyo, JP (1994 - 2004)
  • late of Yokohama, JP (2004)
  • Yokohama, JP (2005)

Company Filing History:

goldMedal11 out of 613 
 
Sankyo Company, Limited
 patents

Years Active: 1994-2005

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6972323 - Anti-Fas antibodies (2005-12-06),
2. 6746673 - Pharmaceutical compositions containing anti-Fas antibody (2004-06-08),
3. 6743611 - Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide (2004-06-01),
4. 6307038 - Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide (2001-10-23),
5. 5955072 - Expression systems utilizing autolyzing fusion proteins and a reducing (1999-09-21),
6. 5830695 - Actinomycete promoter (1998-11-03),
7. 5827855 - Hexahydronaphthalene ester derivatives their preparation and their (1998-10-27),
8. 5491167 - Hexahydronaphthalene ester derivatives, their preparation and their (1996-02-13),
9. 5451688 - Hexahydronaphthalene ester derivatives, their preparation and their (1995-09-19),
10. 5407826 - Isolated cultures of microorganisms of Clonostachys Cylindrospora, (1995-04-18),
11. 5334517 - Microbial process for the production of trans-4-hydroxy-L-proline (1994-08-02),

Title: The Innovations of Nobufusa Serizawa

Introduction

Nobufusa Serizawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-Fas antibodies. With a total of 11 patents to his name, Serizawa's work has the potential to impact the treatment of various autoimmune diseases.

Latest Patents

Among his latest patents is the development of anti-Fas antibodies that are cross-reactive with both mouse and human Fas. These antibodies are useful in treating conditions related to abnormalities in the Fas/Fas ligand system. Another notable patent is a pharmaceutical composition containing an anti-human Fas antibody that induces apoptosis. This composition is designed for the prophylaxis and treatment of autoimmune diseases or rheumatoid arthritis. It allows for a reduced amount of anti-Fas antibody to be used, decreasing the likelihood of patients developing tolerance to the treatment.

Career Highlights

Throughout his career, Nobufusa Serizawa has worked with notable companies, including Sankyo Company, Limited and Sankto Company, Limited. His innovative work in the pharmaceutical industry has garnered attention and respect from his peers.

Collaborations

Some of his notable coworkers include Tohru Takahashi and Ryuta Koishi. Their collaborative efforts have contributed to the advancements in the field of immunology and pharmaceutical sciences.

Conclusion

Nobufusa Serizawa's contributions to the field of pharmaceuticals, particularly through his patents on anti-Fas antibodies, highlight his innovative spirit and dedication to improving medical treatments. His work continues to pave the way for advancements in the treatment of autoimmune diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…